Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium

Abstract | Jun 13, 2024

Author

Zeidner J, et al.

Congress

European Hematology Association Annual Congress

Madrid, Spain | June 13 – 16, 2024